Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-10-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00004110

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: etoposide
Drug: gemtuzumab ozogamicin
Drug: idarubicin
Drug: mitoxantrone hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2012-08-27

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 472

Registration Number: NCT00052299

Locations: 🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇦🇹
A. oe. Krankenhaus der Barmherzigen Schwestern Kinderabteilung, Linz, Austria

and more 52 locations

Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-18

Lead Sponsor: Children's Hospital Los Angeles

Registration Number: NCT00006258

Locations: 🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇨🇦
Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: estramustine
Drug: etoposide
Drug: flutamide
Drug: goserelin
Drug: leuprolide
Drug: nilutamide
Drug: paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-16

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 41

Registration Number: NCT00028769

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States

and more 88 locations

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002982

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

Phase 3

Completed

Conditions: Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 270

Registration Number: NCT00002596

Locations: 🇺🇸
FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 150 locations

Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Lymphoma Trials Office

Target Recruit Count: 310

Registration Number: NCT00005867

Locations: 🇬🇧
Horton Hospital, Banbury, England, United Kingdom
🇬🇧
Hinchingbrooke Hospital, Huntingdon, England, United Kingdom
🇬🇧
Hull Royal Infirmary, Hull, England, United Kingdom

and more 43 locations